Catalent has detailed its IPO terms, estimating its share price at between $19 and $22, and planning to list on the NYSE under the symbol CTLT. A provider of delivery technologies and development for drug, biologics and consumer health products, Catalent recorded $1.8 billion in revenues for the fiscal year ended June 30, 2013, with an adjusted EBITDA of $413 million. Its total post-IPO market capitalization, based on the midpoint price, would be $2.4 billion. The Blackstone Group holds an 86.27% pre-IPO stake, while Genstar Capital's stake is 9.42%. Blackstone bought Catalent in April 2007 for $3.3 billion, with Genstar acquiring its minority interest in the deal.